Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Author(s): Paramita Das*, Sharanakumar R. Gumma, Anjali Nayak, Sunil Menghani, Jithendar R. Mandhadi and Padmavathi P. Prabhu

DOI: 10.2174/2772434418666230710142852

DownloadDownload PDF Flyer Cite As
A Rational Approach To Antitubercular Drug Design: Molecular Docking, Prediction of ADME Properties and Evaluation of Antitubercular Activity of Novel Isonicotinamide Scaffold

Page: [148 - 158] Pages: 11

  • * (Excluding Mailing and Handling)

Abstract

Introduction: One of the most devastating and leading diseases is Tuberculosis (TB), caused by Mycobacterium tuberculosis. Even though many synthetic drugs are available in the market, to increase the therapeutic efficacy and reduce toxicity. Isoniazid is the primary drug used in the treatment of tuberculosis.

Methods: The main objective of the study is to perform molecular docking studies and synthesize the derivatives of isonicotinamide along with the anti-tubercular activity. The isonicotinamide derivatives (a-j) are prepared using isoniazid, carbon disulphate, methyl cyanide, and benzaldehyde derivatives and characterized by TLC, IR, 1HNMR, and Mass spectroscopy. The enzyme decaprenylphosphoryl-D-ribose oxidase (DprE1) of M. tuberculosis had good binding capacity with all the ligands revealed in molecular docking studies. In-vitro studies indicated that all the ligands showed anti-tuberculosis with strain M. tuberculosis.

Results: The analysis was based on the binding energy and minimum inhibitory concentration (MIC). The highest and lowest binding energy is -4.22 Kcal/mol (f) and -8.45 Kcal/mol (d), and the MIC for compound d was found to be 644.22 nM. Among all the ligands, compound 5d has the most cytotoxic effect and lower IC50 values and better bioavailability.

Conclusion: This investigation helps in the development of better anti-tubercular therapy.

Graphical Abstract

[1]
Crystal RG. Research opportunities and advances in lung disease. JAMA 2001; 285(5): 612-8.
[http://dx.doi.org/10.1001/jama.285.5.612] [PMID: 11176868]
[2]
Méchaï F, Cordel H, Guglielmetti L, et al. Management of tuberculosis: Are the practices homogeneous in high-income countries? Front Public Health 2020; 8: 443.
[http://dx.doi.org/10.3389/fpubh.2020.00443] [PMID: 33014963]
[3]
Schluger NW. Tuberculosis elimination, research, and respect for persons. Am J Respir Crit Care Med 2019; 199(5): 560-3.
[http://dx.doi.org/10.1164/rccm.201809-1623ED] [PMID: 30339459]
[4]
Forum of international respiratory socities. The global impact of respiratory disease. 2017. Available from: https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf(Accessed November 22, 2022)
[5]
Sandhu G. Tuberculosis: Current situation, challenges and overview of its control programs in India. J Glob Infect Dis 2011; 3(2): 143-50.
[http://dx.doi.org/10.4103/0974-777X.81691] [PMID: 21731301]
[6]
Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003; 16(3): 463-96.
[http://dx.doi.org/10.1128/CMR.16.3.463-496.2003] [PMID: 12857778]
[7]
Glickman MS, Jacobs WR Jr. Microbial pathogenesis of Mycobacterium tuberculosis: Dawn of a discipline. Cell 2001; 104(4): 477-85.
[http://dx.doi.org/10.1016/S0092-8674(01)00236-7] [PMID: 11239406]
[8]
Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: From the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg 2017; 58(1): E9-E12.
[PMID: 28515626]
[9]
Chikhale R, Menghani S, Babu R, et al. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. Eur J Med Chem 2015; 96: 30-46.
[http://dx.doi.org/10.1016/j.ejmech.2015.04.011] [PMID: 25874329]
[10]
Wang P, Batt SM, Wang B, et al. Discovery of novel thiophene-arylamide derivatives as DprE1 inhibitors with potent antimycobacterial activities. J Med Chem 2021; 64(9): 6241-61.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00263] [PMID: 33852302]
[11]
Amado PSM, Woodley C, Cristiano MLS, O’Neill PM. Recent advances of DprE1 inhibitors against Mycobacterium tuberculosis: Computational analysis of physicochemical and ADMET properties. ACS Omega 2022; 7(45): 40659-81.
[http://dx.doi.org/10.1021/acsomega.2c05307] [PMID: 36406587]
[12]
Tuberculosis drugs and mechanisms of action. 2022. Available from: https://www.niaid.nih.gov/diseases-conditions/tbdrugs (Accessed November 22,2022)
[13]
Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: A review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother 2018; 73(5): 1138-51.
[http://dx.doi.org/10.1093/jac/dkx506] [PMID: 29360989]
[14]
Miryan NI, Éndel’man ES, Klebanov BM, et al. Derivatives of pyridinecarboxylic acids synthesis and antiinflammatory property of fluoro derivatives of nicotinamide and isonicotinamide. Pharm Chem J 1977; 11(1): 62-4.
[http://dx.doi.org/10.1007/BF00779122]
[15]
Koca M, Bilginer S. New benzamide derivatives and their nicotinamide/cinnamamide analogs as cholinesterase inhibitors. Mol Divers 2022; 26(2): 1201-12.
[http://dx.doi.org/10.1007/s11030-021-10249-9] [PMID: 34165688]
[16]
Ma Z, Ginsberg A, Melvin S. Antimycobacterium agents, Comprehensive medicinal Chemistry II. New York: Elsevier: New york 2007.
[17]
Barra R, Randolph V, Sumas M, Lanighan K, Lea MA. Effects of nicotinamide, isonicotinamide, and bleomycin on DNA synthesis and repair in rat hepatocytes and hepatoma cells. J Natl Cancer Inst 1982; 69(6): 1353-7.
[PMID: 6183478]
[18]
Fukaya M, Tamura Y, Chiba Y, Tanioka T, Mao J, Inoue Y. Protective effects of nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice. Biochem Biophys Res Commun 2013; 422(1-2): 92-8.
[19]
Munde G, Menghani SS, Kerzare DR, Rarokar RR, Khedekar PB. In-silico studies, synthesis and evaluation of anti-inflammatory activity of novel pyrimidine scaffold. Lett Drug Des Discov 2023; 20(10): 1621-31.
[20]
Kerzare DR, Menghani SS, Rarokar RR, Khedekar PB. Development of novel indole - linked pyrazole as anticonvulsant agents: A molecular hybridization approach. Arch Der Pharma 2020; 354(1): 1-21.
[21]
Primm TP, Franzblau SG. Recent advances in methodologies for the discovery of antimycobacterial drugs. Curr Bioa Comp 2008; 3(3): 201-8.
[22]
Letafat B, Shakeri R, Emami S, et al. Synthesis and in vitro cytotoxic activity of novel chalcone-like agents. Iran J Basic Med Sci 2013; 16(11): 1155-62.
[PMID: 24494068]